Skip to content

White Tea for Prevention of Chemotherapy Induced Mucositis

Can White Tea Prevent Oral Mucositis in Patients Receiving Neoadjuvant or Adjuvant Treatment With Paclitaxel for Breast Cancer? A Randomized Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04440930
Enrollment
88
Registered
2020-06-22
Start date
2020-09-02
Completion date
2023-04-30
Last updated
2023-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Mucositis

Keywords

mucositis, mouth, paclitaxel

Brief summary

The aim of this study is to determine the effectiveness of mouthwash with white tea in the prevention of paclitaxel induced oral mucositis in women with breast cancer.

Detailed description

Oral mucositis is a common side effect from paclitaxel treatment. It can be very painful and compromise nutrition and oral hygiene, and it may increase the risk of infection. Although oral mucositis is a common side effect to chemotherapy, no available treatment is yet available that can effectively prevent or treat oral mucositis. Based on the knowledge that white tea has anti-inflammatory, anti-oxidant and anti-microbial effect, the current study aims to assess the effect of mouth wash with white tea on paclitaxel induced oral mucositis in women with breast cancer. This study is a phase II randomized controlled trial in which eligible patients will be allocated to a control group (CG) and a study group (SG). The CG will use salt water with soda for mouthwash eight to ten times a day and the SG will use white tea for mouthwash five to six times a day.

Interventions

Mouthwash with white tea five to six times a day for nine weeks

OTHERSalt water with soda

Mouthwash with salt water and soda eight to ten times a day for nine weeks

Sponsors

Vejle Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Woman with breast cancer * Planned neoadjuvant or adjuvant paclitaxel treatment * Age ≥ 18 years * Understand and speak Danish * Written and orally informed consent

Exclusion criteria

\- Palliative treatment with paclitaxel

Design outcomes

Primary

MeasureTime frameDescription
Incidence of oral mucositis grade 2 or higher as measured by the Revised Oral Assessment Guide.up to nine weeksNine categories are included in the Revised Oral Assessment Guide tool: voice, lips, mucous, tongue, gums, teeth, saliva, denture and swallowing. Each category is described and rated according to a score of 1 (healthy) to 3 (severe problems).

Secondary

MeasureTime frameDescription
Frequency of daily mouthwashesonce a week over a period of nine weeksNumber of daily mouthwashes will be registered
Frequency of daily tooth brushingsonce a week over a period of nine weeksNumber of daily tooth brushings will be registered
Pain intensity in the oral cavity as measured on the Numeric Rating Scale (NRS).Once a week over a period of nine weeksNumeric Rating Scale 0-10; 0=no pain, 10=worst possible pain
Date of onset of oral mucositis grade 2 or higher as measured by Revised Oral Assessment Guide.Once a week until oral mucositis occurs up to nine weeksNine categories are included in the Revised Oral Assessment Guide tool: voice, lips, mucous, tongue, gums, teeth, saliva, denture and swallowing. Each category is described and rated according to a score of 1 (healthy) to 3 (severe problems).

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026